FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097805230> ?p ?o ?g. }

• W3097805230 endingPage "44" @default.
• W3097805230 startingPage "42" @default.
• W3097805230 abstract "Introduction Chimeric antigen receptor (CAR) T cell therapy has been extremely efficacious in pediatric patients with multiply relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL) with overall remission rates of 81% by three months post-infusion (Maude et al., N Engl J Med, 2018), and achieved FDA approval for this indication. In order for the product to meet the standards of this approval for commercial release, both the leukapheresis and manufactured products must meet a variety of specific requirements, some of which are more stringent than those in these pivotal clinical trials. The Managed Access Program (MAP) provides access to tisagenlecleucel for patients with B-ALL or diffuse large B-cell lymphoma that is out of specification (OOS) for whom repeat leukapheresis is not feasible. Patients may also receive OOS tisagenlecleucel by applying for a single-patient Investigational New Drug (IND). Previous reports have shown no difference in efficacy or toxicity between patients receiving tisagenlecleucel that meets commercial release specifications and those receiving OOS tisagenlecleucel (Grupp, et al., Blood Abstr 614, 2019; Jaglowski, et al., Blood Abstr 627, 2019). This study seeks to evaluate outcomes in pediatric and young adult patients who received tisagenlecleucel via the MAP or a single-patient IND in our Pediatric Real World CAR Consortium (PRWCC). Methods Retrospective data were abstracted from the PRWCC database of patients with relapsed/refractory B-ALL from fifteen different US institutions who received tisagenlecleucel as an FDA-approved therapy outside the context of a clinical trial. Patients whose cellular product was obtained through the MAP (NCT03601442) or with single patient IND approval due having either a cryopreserved leukapheresis product and/or manufactured tisagenlecleucel that did not meet specifications for commercial release were categorized as MAP/IND and those whose product met all release criteria were categorized as standard of care (SOC). Results Among 185 total infused patients in our database, 24 (13%) received tisagenlecleucel either via the MAP (n=14) or a single patient IND (n=10). Baseline patient and disease characteristics were not significantly different for MAP/IND patients versus the SOC cohorts (Table 1). Median duration of follow-up post-CAR T cell infusion for these infused patients was 342.5 days (range 107-780) versus 318 days (range 6-863) for the SOC cohort (p=0.43). Reasons for products being OOS included cell viability &lt;80% (n=17), total nucleated cell count &lt;2x109 in leukapheresis product (n=3), failed interferon gamma release assay (n=2), cryopreserved leukapheresis product collected &gt;9 months prior (n=1), and determination of residual beads &gt;50 beads/3x106cells (n=1). Overall survival at 6- and 12-months was 96% versus 83% and 85% versus 70% for the MAP/IND versus SOC, respectively. Event-free survival at 6- and 12-months was 65% versus 63% and 55% versus 51%, respectively. Probability of continued remission at 6- and 12-months among patients who achieved a complete remission (CR) at day 28 was 79% versus 75% and 66% versus 63% for the MAP/IND versus SOC, respectively (Figure 1). Comparing toxicities between patients in the MAP/IND versus SOC cohorts, cytokine release syndrome (CRS, any grade) occurred in 46% versus 61%, CRS (&gt;grade 3) in 17% versus 19%, immune effector cell-associated neurotoxicity syndrome (ICANS) in 8% versus 22%, and infectious complications in 54% vs. 37%, respectively (p=ns for all). Conclusions In our retrospective cohort evaluating the use of tisagenlecleucel to treat pediatric and young adult patients with relapsed/refractory B-ALL in the real-world setting, neither the efficacy nor safety of tisagenlecleucel seem to be compromised by use of products OOS for commercial release. Larger studies are needed to further delineate specific cut-offs outside of which either efficacy and/or safety may truly be impacted. Disclosures Phillips: Novartis: Membership on an entity's Board of Directors or advisory committees. Stefanski:Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Margossian:Novartis: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Verneris:Novartis: Membership on an entity's Board of Directors or advisory committees; Fate Therapeutics: Consultancy, Current equity holder in publicly-traded company; Bmogen: Consultancy, Current equity holder in publicly-traded company; Uptodate: Consultancy. Myers:Novartis: Consultancy, Honoraria, Other: ELIANA trial Steering Committee, Speakers Bureau. Brown:Janssen: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Qayed:Mesoblast: Consultancy; Novartis: Consultancy. Hermiston:Novartis: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees. Satwani:Mesoblast: Consultancy; Takeda: Consultancy. Curran:Novartis: Consultancy, Research Funding; Celgene: Research Funding; Mesoblast: Consultancy. Mackall:Apricity Health: Consultancy, Current equity holder in private company; Lyell Immunopharma: Consultancy, Current equity holder in private company; BMS: Consultancy; Nektar Therapeutics: Consultancy; Allogene: Current equity holder in publicly-traded company; NeoImmune Tech: Consultancy. Laetsch:Novartis: Consultancy, Research Funding; Bayer: Research Funding; Pfizer: Research Funding; Cellectis: Consultancy." @default.
• W3097805230 created "2020-11-09" @default.
• W3097805230 creator A5002775135 @default.
• W3097805230 creator A5003624567 @default.
• W3097805230 creator A5007182073 @default.
• W3097805230 creator A5009195619 @default.
• W3097805230 creator A5009609420 @default.
• W3097805230 creator A5010654088 @default.
• W3097805230 creator A5020712214 @default.
• W3097805230 creator A5032213529 @default.
• W3097805230 creator A5034838437 @default.
• W3097805230 creator A5035520605 @default.
• W3097805230 creator A5039605313 @default.
• W3097805230 creator A5042193226 @default.
• W3097805230 creator A5048733835 @default.
• W3097805230 creator A5051925691 @default.
• W3097805230 creator A5052844124 @default.
• W3097805230 creator A5055001531 @default.
• W3097805230 creator A5057939769 @default.
• W3097805230 creator A5061884188 @default.
• W3097805230 creator A5066186106 @default.
• W3097805230 creator A5067283337 @default.
• W3097805230 creator A5084882436 @default.
• W3097805230 creator A5084893250 @default.
• W3097805230 creator A5085555874 @default.
• W3097805230 creator A5087115676 @default.
• W3097805230 creator A5087189305 @default.
• W3097805230 creator A5087456665 @default.
• W3097805230 creator A5087551014 @default.
• W3097805230 creator A5087779758 @default.
• W3097805230 date "2020-11-05" @default.
• W3097805230 modified "2023-10-01" @default.
• W3097805230 title "Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release" @default.
• W3097805230 doi "https://doi.org/10.1182/blood-2020-136674" @default.
• W3097805230 hasPublicationYear "2020" @default.
• W3097805230 type Work @default.
• W3097805230 sameAs 3097805230 @default.
• W3097805230 citedByCount "7" @default.
• W3097805230 countsByYear W30978052302021 @default.
• W3097805230 countsByYear W30978052302022 @default.
• W3097805230 crossrefType "journal-article" @default.
• W3097805230 hasAuthorship W3097805230A5002775135 @default.
• W3097805230 hasAuthorship W3097805230A5003624567 @default.
• W3097805230 hasAuthorship W3097805230A5007182073 @default.
• W3097805230 hasAuthorship W3097805230A5009195619 @default.
• W3097805230 hasAuthorship W3097805230A5009609420 @default.
• W3097805230 hasAuthorship W3097805230A5010654088 @default.
• W3097805230 hasAuthorship W3097805230A5020712214 @default.
• W3097805230 hasAuthorship W3097805230A5032213529 @default.
• W3097805230 hasAuthorship W3097805230A5034838437 @default.
• W3097805230 hasAuthorship W3097805230A5035520605 @default.
• W3097805230 hasAuthorship W3097805230A5039605313 @default.
• W3097805230 hasAuthorship W3097805230A5042193226 @default.
• W3097805230 hasAuthorship W3097805230A5048733835 @default.
• W3097805230 hasAuthorship W3097805230A5051925691 @default.
• W3097805230 hasAuthorship W3097805230A5052844124 @default.
• W3097805230 hasAuthorship W3097805230A5055001531 @default.
• W3097805230 hasAuthorship W3097805230A5057939769 @default.
• W3097805230 hasAuthorship W3097805230A5061884188 @default.
• W3097805230 hasAuthorship W3097805230A5066186106 @default.
• W3097805230 hasAuthorship W3097805230A5067283337 @default.
• W3097805230 hasAuthorship W3097805230A5084882436 @default.
• W3097805230 hasAuthorship W3097805230A5084893250 @default.
• W3097805230 hasAuthorship W3097805230A5085555874 @default.
• W3097805230 hasAuthorship W3097805230A5087115676 @default.
• W3097805230 hasAuthorship W3097805230A5087189305 @default.
• W3097805230 hasAuthorship W3097805230A5087456665 @default.
• W3097805230 hasAuthorship W3097805230A5087551014 @default.
• W3097805230 hasAuthorship W3097805230A5087779758 @default.
• W3097805230 hasConcept C10205521 @default.
• W3097805230 hasConcept C121332964 @default.
• W3097805230 hasConcept C121608353 @default.
• W3097805230 hasConcept C126322002 @default.
• W3097805230 hasConcept C141071460 @default.
• W3097805230 hasConcept C142424586 @default.
• W3097805230 hasConcept C143998085 @default.
• W3097805230 hasConcept C151730666 @default.
• W3097805230 hasConcept C2776694085 @default.
• W3097805230 hasConcept C2777371436 @default.
• W3097805230 hasConcept C2777396833 @default.
• W3097805230 hasConcept C2777701055 @default.
• W3097805230 hasConcept C2778020697 @default.
• W3097805230 hasConcept C2778461978 @default.
• W3097805230 hasConcept C2779343474 @default.
• W3097805230 hasConcept C2780775027 @default.
• W3097805230 hasConcept C2780850621 @default.
• W3097805230 hasConcept C28328180 @default.
• W3097805230 hasConcept C2909962599 @default.
• W3097805230 hasConcept C3875195 @default.
• W3097805230 hasConcept C54355233 @default.
• W3097805230 hasConcept C71924100 @default.
• W3097805230 hasConcept C86803240 @default.
• W3097805230 hasConcept C87355193 @default.
• W3097805230 hasConceptScore W3097805230C10205521 @default.
• W3097805230 hasConceptScore W3097805230C121332964 @default.
• W3097805230 hasConceptScore W3097805230C121608353 @default.
• W3097805230 hasConceptScore W3097805230C126322002 @default.
• W3097805230 hasConceptScore W3097805230C141071460 @default.

• next